How Does Teduglutide Work? Mechanism of Action, Per the Research

Teduglutide is discussed in the pharmacology literature as a peptide analogue of glucagon-like peptide-2 (GLP-2), an endogenous gut hormone. A historical review of the field traced the discovery of GLP-2 as a proglucagon-derived peptide released from intestinal enteroendocrine L cells and the subsequent development of teduglutide as a degradation-resistant analogue intended for short bowel syndrome (PMID 32219218). This page summarises how that mechanism is described in published sources and distinguishes what is established receptor pharmacology from what remains proposed. Readers looking for the broader background can also see the teduglutide overview. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

What Teduglutide Is, in Pharmacological Terms

In the review that traced the hormone's discovery, GLP-2 was described as a 33-amino-acid peptide cleaved from proglucagon in intestinal L cells, with teduglutide developed as an analogue of that sequence (PMID 32219218). A drug review of teduglutide in short bowel syndrome characterised the compound as a recombinant GLP-2 analogue that acts as an agonist at the GLP-2 receptor (PMID 28194723). In other words, the molecule was not designed to introduce a new biological pathway; it was designed to engage an existing one for longer than the natural hormone does.

Teduglutide is approved in multiple regions as a prescription product for short bowel syndrome, and a review of short bowel syndrome pharmacotherapy placed it among the agents developed specifically to act on intestinal absorptive capacity rather than simply to slow transit (PMID 32057270). Research-use-only peptide material sold outside that regulatory pathway is not the same as an approved medicinal product.

The Biological System the Drug Targets

Where GLP-2 comes from

The discovery review described GLP-2 as a product of proglucagon processing in enteroendocrine L cells of the distal small intestine and colon, released in response to luminal nutrients (PMID 32219218). That anatomical detail matters mechanistically: in people who have lost distal small bowel or colon, the tissue that secretes the hormone may itself be reduced. Reviews of short bowel syndrome have described the condition as the consequence of extensive resection or loss of functional absorptive surface (PMID 37115031), which is the clinical setting in which GLP-2 pharmacology has been most studied.

The receptor and indirect signalling

The GLP-2 receptor is a G protein-coupled receptor, and the discovery review noted that it is not expressed uniformly on absorptive enterocytes but rather on a limited set of intestinal cell types, so that the growth signal reaching the epithelium is largely indirect (PMID 32219218). This indirect architecture is the single most important structural point in the mechanism: the peptide binds to one cell population, and other mediators carry the message to the cells that actually expand the absorptive surface. Reviews of intestinal adaptation after resection have likewise framed epithelial growth as the product of multiple interacting hormonal, neural and luminal signals rather than a single ligand acting alone (PMID 24586019).

Why an Analogue Rather Than the Natural Hormone

Native GLP-2 is cleaved rapidly by dipeptidyl peptidase-4 (DPP-4), and the discovery review described the development of teduglutide as a structural modification at the second amino acid position intended to resist that enzymatic cleavage (PMID 32219218). The drug review of teduglutide in short bowel syndrome similarly described the molecule as a longer-acting GLP-2 analogue developed for clinical use (PMID 28194723). The pharmacological logic is therefore conventional analogue design: preserve receptor affinity, remove the fastest route of degradation, and obtain a longer window of receptor engagement than the endogenous peptide achieves.

Downstream Physiology Described in the Literature

What happens after the receptor is engaged is usually described in three broad categories.

• Mucosal growth and absorptive surface. The drug review described teduglutide as promoting growth of the intestinal mucosa with the aim of improving intestinal absorption in short bowel syndrome (PMID 28194723).
• Intestinal adaptation signalling. A review of adaptation following resection described the remnant bowel as undergoing structural and functional remodelling in which trophic signalling pathways are a central component (PMID 24586019), and a further review of adaptation after enterectomy summarised progress in understanding the hormonal and cellular drivers of that process (PMID 36562240).
• Pharmacological role in malabsorption management. A review of short bowel syndrome pharmacotherapy discussed GLP-2 analogue therapy alongside other agents used to address intestinal failure (PMID 32057270), and European consensus documents on malabsorption addressed nutritional goals and supportive care in these populations (PMID 40088199).

It is worth stating plainly what this page does not do: it does not describe dosing, administration or expected outcomes for any individual. The mechanism literature describes a pathway; it does not forecast what a given person would experience.

Human Mechanistic Evidence

Most mechanistic detail historically came from laboratory models, but more recent work has examined human tissue directly. Researchers conducting a longitudinal single-cell analysis of GLP-2 treatment in patients with short bowel syndrome profiled intestinal tissue over time to characterise cellular responses at the transcriptional level (PMID 40773292). The study design, sampling the same patients across time points rather than comparing separate groups, is the kind of approach that can connect receptor-level pharmacology to changes in specific cell populations within the human intestinal mucosa (PMID 40773292).

Separately, pediatric literature has considered whether the same mechanism applies in growing intestine; a review of teduglutide in pediatric short bowel syndrome patients summarised the evidence base in that age group (PMID 33798402). Developmental differences in intestinal remodelling are one reason mechanism cannot be assumed to transfer unchanged between adult and pediatric populations (PMID 33798402).

Animal and Ex Vivo Work, Labelled as Such

Some of the most frequently cited mechanistic observations come from non-human models and should be read that way. In a mouse study, researchers reported that GLP-2 prevented antipsychotic-induced metabolic dysfunction, an observation that extended interest in GLP-2 receptor signalling beyond the intestinal mucosa toward metabolic regulation (PMID 40114026). That study was conducted in mice and examined GLP-2 biology rather than teduglutide outcomes in people, so it belongs in the "proposed, model-derived" column rather than the established human mechanism column (PMID 40114026).

Ex vivo patient-derived systems are also used in gastrointestinal pharmacology more broadly; a report on personalised drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms illustrated how tissue-derived models are applied to test drug responses outside the body (PMID 41518601). Such platforms describe cellular behaviour in a dish and do not, on their own, establish clinical mechanism (PMID 41518601).

Established Mechanism Versus Proposed Mechanism

Mechanism-Linked Effects and Tolerability: What Studies Report

Because the proposed mechanism is trophic, that is, growth-promoting in intestinal tissue, the safety discussion in the literature follows directly from the pharmacology. The drug review of teduglutide in short bowel syndrome addressed the tolerability profile alongside efficacy data in its assessment of the agent (PMID 28194723), and the pediatric review similarly considered safety considerations specific to children (PMID 33798402). A review of short bowel syndrome pharmacotherapy discussed the practical considerations that accompany use of agents in this class within intestinal failure care (PMID 32057270). European consensus work on malabsorption addressed screening, special populations and supportive care, which is the clinical framework in which monitoring decisions sit (PMID 40088199). Specific adverse-event frequencies, monitoring intervals and prescribing criteria are matters for prescribing information and treating clinicians, not for an educational summary.

What the Mechanism Does Not Explain

Three limits are visible in the published material. First, receptor engagement is not the same as clinical benefit; reviews of adaptation after resection described a multifactorial process in which luminal nutrition, anatomy and remnant bowel length all contribute (PMID 24586019, PMID 36562240). Second, the patient population is heterogeneous; consensus work on malabsorption described a range of clinical phenotypes and diagnostic routes that sit behind a single diagnostic label (PMID 40129317), and short bowel syndrome itself has been classified by anatomy and cause rather than treated as one entity (PMID 37115031). Third, mechanistic findings reported in mice describe mouse physiology until replicated in people (PMID 40114026).

In short, the published account of how teduglutide works is reasonably well defined at the receptor level and less fully resolved at the tissue level, which is precisely why human single-cell studies of GLP-2 treatment were undertaken (PMID 40773292). This page summarises literature only and is not a substitute for individualised medical advice from a licensed physician.

References

• The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome (ACS Pharmacology & Translational Science, 2019)
• Teduglutide: A Review in Short Bowel Syndrome (Drugs, 2017)
• Treating short bowel syndrome with pharmacotherapy (Expert Opinion on Pharmacotherapy, 2020)
• Teduglutide for pediatric short bowel syndrome patients (Expert Review of Gastroenterology & Hepatology, 2021)
• Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome (JCI Insight, 2025)
• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice (Nature Metabolism, 2025)
• Intestinal adaptation following resection (JPEN. Journal of Parenteral and Enteral Nutrition, 2014)
• Progress in intestinal adaptation after enterectomy (Chinese Journal of Gastrointestinal Surgery, 2022)
• Definition, classification, and causes of short bowel syndrome (Nutrition in Clinical Practice, 2023)
• European Consensus on Malabsorption, Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing (United European Gastroenterology Journal, 2025)
• European Consensus on Malabsorption, Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care (United European Gastroenterology Journal, 2025)
• Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms (Journal of Clinical Endocrinology and Metabolism, 2026)